CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety.



Godói, Isabella Piassi ORCID: 0000-0002-0568-6625, Lemos, Livia Lovato Pires, de Araújo, Vânia Eloisa, Bonoto, Braúlio Cesar, Godman, Brian ORCID: 0000-0001-6539-6972 and Guerra Júnior, Augusto Afonso ORCID: 0000-0001-5256-0577
(2017) CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety. Journal of comparative effectiveness research, 6 (2). pp. 165-180.

[thumbnail of Accepted for publication.doc] Text
Accepted for publication.doc - Author Accepted Manuscript

Download (990kB)

Abstract

<h4>Introduction</h4>Dengue virus (DENV) is a serious global health problem. CYD-TDC (Dengvaxia<sup>®</sup>) was the first vaccine to gain regulatory approval to try and address this problem.<h4>Aim</h4>Summarize all available evidence on the immunogenicity, efficacy and safety of the CYD-TDV dengue vaccine.<h4>Method</h4>Meta-analysis and systematic review.<h4>Results</h4>The best and worst immunogenicity results were for DENV4 and DENV1, respectively. Vaccine efficacy of 60% was derived from studies with participants aged 2-16 years old, with DENV4 and DENV2 presenting the best and worst results, respectively. Erythema and swelling were more frequent with CYD-TDV. No differences were detected for systemic adverse events.<h4>Conclusion</h4>CYD-TDV showed moderate efficacy in children and adolescents. From the immunogenicity results in adults, we can expect satisfactory efficacy from vaccination in this population.

Item Type: Article
Uncontrolled Keywords: Humans, Dengue, Treatment Outcome, Adolescent, Child, Child, Preschool, Female, Male, Dengue Vaccines, Adaptive Immunity, Patient Safety, Immunogenicity, Vaccine
Depositing User: Symplectic Admin
Date Deposited: 13 Jun 2017 07:28
Last Modified: 17 Mar 2024 13:45
DOI: 10.2217/cer-2016-0045
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3007940